NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia

NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma

NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma

A Phase1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral irreversible menin inhibitor, in adult patients with acute leukemia, diffuse large B-cell lymphoma, and multiple myeloma

Sponsor

Biomea Fusion Inc.

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT05153330

Official Title: COVALENT-101: A Phase1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Irreversible Menin Inhibitor, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), and Multiple Myeloma (MM)

First Posted : December 10, 2021

Click here to see details on ClinicalTrials.gov

---

Drug: BMF-219

---

BMF 219

Menin Inhibitor BMF-219 (Code C185864)

BMF 219

BMF-219

BMF219

Menin Inhibitor BMF-219

Menin-MLL Interaction Inhibitor BMF-219

---

Locations

United States, California

United States, Florida

United States, Ohio

United States, Tennessee

United States, Texas